Wistar Scientists Find FDA-Approved Drug Halts EBV-Driven Lymphoma by Disrupting a Key Cancer Pathway
July 11, 2025
July 11, 2025
PHILADELPHIA, Pennsylvania, July 11 (TNSjou) -- The Wistar Institute issued the following news release on July 10, 2025:
* * *
Wistar Scientists Find FDA-Approved Drug Halts EBV-Driven Lymphoma by Disrupting a Key Cancer Pathway
PHILADELPHIA -- (July 10, 2025) -- Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings . . .
* * *
Wistar Scientists Find FDA-Approved Drug Halts EBV-Driven Lymphoma by Disrupting a Key Cancer Pathway
PHILADELPHIA -- (July 10, 2025) -- Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings . . .